Chanca Piedra for Uric Acid, Gout, and Hypertension

Chanca Piedra has measurable but mild xanthine oxidase inhibition, modest uricosuric effects, a gentle diuretic action, and ACE-inhibitor-like activity from its tannins. None of these effects rival prescription medications, but together they form a coherent secondary indication: an adjunct for borderline hyperuricemia, mild stage 1 hypertension, or as a complement to standard therapy. This page covers the pharmacology, the human evidence (such as it is), and where Chanca Piedra reasonably fits.

Table of Contents

1. Xanthine Oxidase Inhibition
2. Animal Hyperuricemia Models
3. Human Studies in Gout and Hyperuricemia
4. Diuretic Effect
5. ACE-Inhibitor-Like Activity
6. Blood Pressure Effects
7. Combination with Conventional Gout Therapy
8. Combination with Antihypertensives
9. Dosing
10. Patient-Facing Reality
11. Research Papers and References
12. Connections

Xanthine Oxidase Inhibition

Xanthine oxidase is the enzyme that produces uric acid from hypoxanthine and xanthine. Inhibiting it lowers serum urate, the basis for the prescription drugs allopurinol and febuxostat. Methanolic and ethanolic extracts of P. niruri and P. amarus inhibit xanthine oxidase in vitro with IC50 values typically in the 30–150 µg/mL range (Murugaiyah and Chan 2007 and others). The active fractions are lignans (phyllanthin, hypophyllanthin) and ellagitannins (geraniin, corilagin), with flavonoids (rutin, quercetin glycosides) contributing.

Magnitude vs. allopurinol: 10–100× weaker on a weight basis. Allopurinol IC50 is approximately 0.2–1 µg/mL; febuxostat is sub-nanomolar. Chanca Piedra is a real but mild xanthine oxidase inhibitor.

Animal Hyperuricemia Models

Potassium-oxonate-induced hyperuricemic rodents fed Phyllanthus extracts at 100–400 mg/kg show 20–45% serum urate reduction with dose-response. Allopurinol at 10 mg/kg in the same models drops urate 50–70%. So animal data confirm the in-vitro signal, but at supraphysiologic doses (rodent mg/kg translates roughly 6× smaller in humans, so 400 mg/kg in a rat is approximately 65 mg/kg in a 70 kg adult, or about 4.5 g/day — at the upper end of clinical Chanca Piedra dosing).

Human Studies in Gout and Hyperuricemia

Very thin. A few small open-label or pilot trials, mostly Brazilian or Indian, report:

• Modest serum urate drops of 0.5–1.5 mg/dL over 4–8 weeks
• Effect proportional to baseline urate level (more reduction at higher starting points)
• Improved 24-hour urinary urate excretion

No large RCT exists for gout or chronic hyperuricemia. Don't promise gout cure or substitution for allopurinol/febuxostat in patients with established disease.

Diuretic Effect

Chanca Piedra produces a mild aquaretic / mild natriuretic effect — closest to a weak thiazide-like or osmotic profile, not loop-diuretic-style, not potassium-sparing. Specifically:

• Urine volume increases by approximately 15–25% in rat studies; smaller human data suggest similar mild effect
• Sodium loss is modest
• Potassium loss is minimal — a relative advantage over thiazides and loop diuretics

For stone formers and hypertensives, the diuretic effect is a benefit. For patients with low blood pressure or volume depletion, it could be a problem; monitor.

ACE-Inhibitor-Like Activity

Geraniin and corilagin show in-vitro angiotensin-converting enzyme inhibition with IC50 values around 10–50 µM. The mechanism is tannin-mediated zinc chelation at the ACE active site — a different molecular interaction than prescription ACE inhibitors (which bind the catalytic domain) but similar net effect. This is in-vitro pharmacology, not clinical proof. The translation to human BP-lowering depends on whether enough of the active compounds reach the target tissue at meaningful concentrations.

Blood Pressure Effects

Animal data: spontaneously hypertensive rat (SHR) studies show 10–20 mmHg systolic reductions at 200–400 mg/kg.

Human data: a 2018 Indonesian RCT (~70 patients with mild hypertension) showed approximately 7–10 mmHg systolic blood-pressure reduction over 12 weeks. Preliminary but consistent with the animal signal.

For perspective: a typical thiazide diuretic produces 10–15 mmHg systolic reduction; a single ACE inhibitor at standard dose produces 10–15 mmHg reduction; combination therapy produces 20+ mmHg reduction. Chanca Piedra at the bottom end of this range.

Combination with Conventional Gout Therapy

No documented dangerous interactions with allopurinol, febuxostat, colchicine, or NSAIDs. Theoretically additive on urate (allopurinol blocks production via xanthine oxidase; Chanca Piedra mildly does the same plus mildly increases excretion). For most gout patients, the additive effect would be modest.

Caveat: Phyllanthus mildly inhibits CYP3A4 and CYP2C9, which could affect plasma levels of colchicine and certain NSAIDs. Space dosing by 2 hours; monitor for unusual side effects.

Combination with Antihypertensives

Additive blood-pressure-lowering with ACE inhibitors, ARBs, thiazides, or calcium-channel blockers. Realistic risk: mild hypotension or dizziness, not crisis. Recommendations:

• Monitor blood pressure for the first 2–4 weeks of combination
• Avoid stacking with potassium-sparing diuretics (spironolactone, eplerenone) if you have CKD — theoretical hyperkalemia risk via the ACE-like mechanism
• Avoid stacking with multiple antihypertensives plus Chanca Piedra in elderly patients prone to orthostasis

Dosing

• Standardized extract (4:1 or 10:1, 3–5% phyllanthin): 500 mg twice daily with food
• Whole-herb capsules: 1–2 g/day total
• Tea: 1–2 tsp dried herb in 8 oz water, twice daily
• Cycle: 8 weeks on, 2 weeks off if used long-term — long-term safety data are limited

Patient-Facing Reality

Chanca Piedra is a mild adjunct for these indications, not a primary therapy. Reasonable scenarios:

• Borderline hyperuricemia (serum urate 7–8 mg/dL) without tophi or recurrent flares
• Stage 1 hypertension (BP 130–139 / 80–89 mmHg) where lifestyle is the primary intervention and a mild adjunct is welcome
• Already on allopurinol with mild persistent hyperuricemia, looking for additional support
• Already on a single antihypertensive with BP not quite at goal, considering combination options

Inappropriate scenarios:

• Acute gout flare (Chanca Piedra is preventive/adjunctive, not for flare control — use NSAIDs, colchicine, or steroids)
• Serum urate > 10 mg/dL or recurrent gout (needs allopurinol or febuxostat)
• Established cardiovascular disease (use evidence-based pharmacotherapy)
• Pregnancy

Back to Table of Contents

Research Papers and References

1. Phyllanthus and xanthine oxidase — PubMed
2. P. amarus hyperuricemia — PubMed
3. Geraniin ACE inhibition — PubMed
4. Phyllanthus and hypertension — PubMed
5. Corilagin and uric acid — PubMed
6. Murugaiyah XO inhibition — PubMed

Back to Table of Contents

Connections

• Chanca Piedra Deep-Dive Articles:
• Chanca Piedra Overview
• Kidney Stone Protocol
• Active Compounds
• Safety
• Related Tests & Conditions:
• Uric Acid Test
• Rheumatology (Gout)
• Hypertension
• Cardiology
• Coronary Calcium Score
• Potassium
• Magnesium

Back to Table of Contents